Estonia - estone - Ravimiamet

sun pharmaceutical industries europe b.v. - mifepristoon+misoprostool - tablett + vaginaaltablett - 200mg+0/0+0,2mg 1tk / 4tk; 200mg+0/0+0,2mg 30tk / 120tk

Estonia - estone - Ravimiamet

exelgyn - misoprostool - tablett - 400mcg 4tk; 400mcg 16tk; 400mcg 40tk; 400mcg 1tk

Estonia - estone - Ravimiamet

exelgyn - mifepristoon - tablett - 200mg 15tk; 200mg 1tk; 200mg 3tk

Estonia - estone - Ravimiamet

merck sharp & dohme b.v. - kooriongonadotropiin - süstelahuse pulber ja lahusti - 5000rÜ 1ml 3tk

Estonia - estone - Ravimiamet

first pharma oÜ - mifepristoon - tablett - 200mg 1tk; 200mg 3tk; 200mg 15tk

Estonia - estone - Ravimiamet

ideal trade links uab - mifepristoon - tablett - 200mg 15tk; 200mg 1tk; 200mg 3tk

Unione Europea - estone - EMA (European Medicines Agency)

csl behring gmbh - etranacogene dezaparvovec - hemofiilia b - other hematological agents - treatment of severe and moderately severe haemophilia b (congenital factor ix deficiency) in adult patients without a history of factor ix inhibitors.

Unione Europea - estone - EMA (European Medicines Agency)

kyowa kirin holdings b.v. - burosumab - hypophosphatemia, familial; hypophosphatemic rickets, x-linked dominant; osteomalacia - narkootikumid luuhaiguste raviks - crysvita is indicated for the treatment of x-linked hypophosphataemia, in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease, and in adults. crysvita is indicated for the treatment of fgf23-related hypophosphataemia in tumour-induced osteomalacia associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.

Estonia - estone - Ravimiamet

roche eesti osaühing - alfadornaas - nebuliseeritav lahus - 1mg 1ml 2.5ml 6tk

Unione Europea - estone - EMA (European Medicines Agency)

amryt pharmaceuticals dac - octreotide acetate - akromegaalia - hüpofüüsi ja hüpotaalamuse hormoonid ja analoogid - mycapssa is indicated for maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogues.